348 related articles for article (PubMed ID: 25789840)
21. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic Lymphoma Kinase Immunocytochemistry on Cell-Transferred Cytologic Smears of Lung Adenocarcinoma.
Zhang C; Randolph ML; Jones KJ; Cramer HM; Cheng L; Wu HH
Acta Cytol; 2015; 59(2):213-8. PubMed ID: 25967762
[TBL] [Abstract][Full Text] [Related]
23. Response to pemetrexed rechallenge after acquired resistance of ALK inhibitors.
Miyazaki K; Satoh H; Tamura T
Lung Cancer; 2016 Dec; 102():135. PubMed ID: 27526980
[No Abstract] [Full Text] [Related]
24. Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient.
Hochmair MJ; Schwab S; Prosch H
Anticancer Drugs; 2017 Sep; 28(8):928-930. PubMed ID: 28628492
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
26. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.
Possidente L; Landriscina M; Patitucci G; Borgia L; Lalinga V; Vita G
Med Oncol; 2017 May; 34(5):76. PubMed ID: 28364271
[TBL] [Abstract][Full Text] [Related]
27. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer.
Cutz JC; Craddock KJ; Torlakovic E; Brandao G; Carter RF; Bigras G; Deschenes J; Izevbaye I; Xu Z; Greer W; Yatabe Y; Ionescu D; Karsan A; Jung S; Fraser RS; Blumenkrantz M; Lavoie J; Fortin F; Bojarski A; Côté GB; van den Berghe JA; Rashid-Kolvear F; Trotter M; Sekhon HS; Albadine R; Tran-Thanh D; Gorska I; Knoll JH; Xu J; Blencowe B; Iafrate AJ; Hwang DM; Pintilie M; Gaspo R; Couture C; Tsao MS
J Thorac Oncol; 2014 Sep; 9(9):1255-63. PubMed ID: 25122422
[TBL] [Abstract][Full Text] [Related]
28. [Expression of ALK protein in 7 371 pulmonary adenocarcinoma samples, with analysis of clinicopathologic features].
Zhao RY; Zhang J; Zhu L; Shao JC; Zhang Q; Teng HH; Qin G; Zhao LX; Ye M; Zhao JK; Ding WJ
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):601-5. PubMed ID: 27646887
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement.
Lin D; Zeng D; Chen C; Wu X; Wang M; Chen J; Lin H; Qiu X
Oncol Res Treat; 2017; 40(1-2):27-33. PubMed ID: 28118634
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG
J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158
[No Abstract] [Full Text] [Related]
31. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
32. Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review.
Sasano H; Sekine A; Hirata T; Iwamoto K; Itou Y; Itani H; Kondou S; Tokui T; Tanigawa M
Intern Med; 2018 Nov; 57(22):3271-3275. PubMed ID: 29984766
[TBL] [Abstract][Full Text] [Related]
33. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain Metastases].
Lv J; Zhang Q; Qin N; Yang X; Zhang X; Wu Y; Li X; Zhang H; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):519-24. PubMed ID: 27561801
[TBL] [Abstract][Full Text] [Related]
35. ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.
Martin V; Bernasconi B; Merlo E; Balzarini P; Vermi W; Riva A; Chiaravalli AM; Frattini M; Sahnane N; Facchetti F; Mazzucchelli L; Sessa F; Tibiletti MG
J Thorac Oncol; 2015 Apr; 10(4):595-602. PubMed ID: 25514802
[TBL] [Abstract][Full Text] [Related]
36. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma.
Kamide Y; Kaira K; Watanabe T; Kuribayashi S; Ozawa A; Koga Y; Ono A; Sunaga N; Hisada T; Oyama T; Yamada M
Intern Med; 2015; 54(22):2905-9. PubMed ID: 26568007
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.
Bernicker EH; Miller RA; Cagle PT
J Oncol Pract; 2017 Apr; 13(4):221-227. PubMed ID: 28399384
[TBL] [Abstract][Full Text] [Related]
39. Early brain recurrences are potentially detectable in asymptomatic, early stage lung adenocarcinoma.
Nelson JS; Allen LD; Parker LA; Hayward MC; Zhao N; Hayes DN
Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):718-20. PubMed ID: 21945387
[No Abstract] [Full Text] [Related]
40. Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
Wardak Z; Choy H
J Clin Oncol; 2016 Dec; 34(34):4064-4065. PubMed ID: 27863198
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
